Cell Therapeutics announces latest trial results for Zevalin

01/22/2009 | RTT News

Patients with mucosa-associated lymphoid tissue lymphoma and low-grade follicular lymphoma in conjunctiva exhibited an 83% complete response rate to Zevalin, Cell Therapeutics' radioimmunotherapy, during a front-line study. The results show that Zevalin could be a good alternative to current treatments, providing lower ocular toxicity and equal or better disease control, said the company's chief medical officer.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL